Chemoembolization for liver metastases from medullary thyroid carcinoma.

Details

Serval ID
serval:BIB_963F663C4CDC
Type
Article: article from journal or magazin.
Collection
Publications
Title
Chemoembolization for liver metastases from medullary thyroid carcinoma.
Journal
The Journal of clinical endocrinology and metabolism
Author(s)
Fromigué J., De Baere T., Baudin E., Dromain C., Leboulleux S., Schlumberger M.
ISSN
0021-972X (Print)
ISSN-L
0021-972X
Publication state
Published
Issued date
07/2006
Peer-reviewed
Oui
Volume
91
Number
7
Pages
2496-2499
Language
english
Notes
Publication types: Case Reports ; Journal Article ; Review
Publication Status: ppublish
Abstract
Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor. Distant metastases are the main cause of cancer-related death. Systemic chemotherapy produces only rare tumor responses. Somatostatin analogs and other available modalities are poorly effective to control symptoms.
The aim of our study was to evaluate the impact of liver transarterial chemoembolization (TACE) in MTC patients with predominant and progressive liver metastases.
Twelve MTC patients underwent 18 TACE courses (mean, 1.5; range, 1-2). Response evaluation criteria in solid tumors were used to evaluate tumor responses. Symptomatic responses were defined by more than a 25% decrease of symptoms intensity.
Partial radiological tumor response was obtained in five patients (42%) with a median duration of 17 months (mean, 19; range, 15-28 months), stabilization in five (42%) with a median duration of 24 months (mean, 24; range, 4-39 months), and progression in the remaining two (16%). The five partial tumor responses were observed in the nine patients with less than 30% liver involvement. Clinical response was observed in two of the five patients with diarrhea. Carcinoembryonic antigen did not appear to be a useful marker in this setting. Significant grade 3-4 toxicity was observed in one patient who had a major tumor necrosis after TACE.
TACE should be considered for treating MTC patients with progressive and predominant liver metastasis, and preferably at an early stage during the course of metastatic disease.
Keywords
Adult, Aged, Aged, 80 and over, Calcitonin/blood, Carcinoembryonic Antigen/blood, Carcinoma, Medullary/secondary, Chemoembolization, Therapeutic/adverse effects, Chemoembolization, Therapeutic/methods, Female, Humans, Liver/blood supply, Liver Neoplasms/diagnostic imaging, Liver Neoplasms/secondary, Liver Neoplasms/therapy, Male, Middle Aged, Thyroid Neoplasms, Tomography, X-Ray Computed, Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
16/09/2016 11:14
Last modification date
12/05/2025 15:17
Usage data